Embed Size (px)
DESCRIPTION
Breast Cancer Highlights: San Antonio, 2012. N9831/B31: DFS and OS (8-Year Follow-up). B31/N9831:Cumulative Incidence of Distant Recurrence as a First Event. Duration of Adjuvant Trastuzumab (8-Year Follow-up): OS -- 2 y vs 1 y. ATLAS: 10 vs 5 Years of Tamoxifen. - PowerPoint PPT Presentation
Citation preview
